About Phillips Medisize
Phillips Medisize is a company based in Chippenham (United Kingdom) founded in 1997 was acquired by Phillips Medisize in May 2025. It operates as a Professional Services and Reseller / Distribution. Phillips Medisize has raised $15.21 million across 2 funding rounds from investors including Boehringer Ingelheim, Molex and Philip Morris International. Phillips Medisize has completed 3 acquisitions, including Activaero, Skyepharma and Syqe. Phillips Medisize offers products and services including Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector. Phillips Medisize operates in a competitive market with competitors including Nephron Pharmaceuticals, Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm and Suanfarma, among others.
- Headquarter Chippenham, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Phillips Medisize – A Molex Company
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.21 M (USD)
in 2 rounds
-
Latest Funding Round
$21.76 M (USD), Post-IPO
Nov 26, 2007
-
Investors
Boehringer Ingelheim
& 4 more
-
Employee Count
Not available
-
Investments & Acquisitions
Activaero
& 2 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Phillips Medisize
Phillips Medisize offers a comprehensive portfolio of products and services, including Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector.
Devices for delivering dry powder inhalation therapies effectively.
Inhalers providing metered doses for respiratory treatment solutions.
Nebulizer using vibrating mesh for efficient drug delivery.
Smart autoinjector designed for precise drug administration ease.
People of Phillips Medisize
Unlock access to complete
Funding Insights of Phillips Medisize
Phillips Medisize has successfully raised a total of $15.21M across 2 strategic funding rounds. The most recent funding activity was a Post-IPO round of $21.76 million completed in November 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Phillips Medisize
Phillips Medisize has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Boehringer Ingelheim, Molex and Philip Morris International.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments are managed across the UK.
|
Locked | Locked | Locked | |
|
Generic drugs and clinical research services are provided globally.
|
Locked | Locked | Locked | |
|
Communication equipment manufacturer
|
Locked | Locked | Locked |
Investor details for Phillips Medisize
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Phillips Medisize
Phillips Medisize has strategically engaged in corporate development activities, having acquired 3 companies. Notable acquisitions include Activaero, Skyepharma and Syqe.
Investment portfolio details for Phillips Medisize
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Precise dosing inhaler for medical cannabis is developed.
|
Locked | Locked | 2011 | Locked | |
|
Controlled breathing technologies for inhaler devices were developed.
|
Locked | Locked | 2004 | Locked | |
|
Developer of small molecule based oral and inhalation products for the treatment of various diseases
|
Locked | Locked | 1996 | Locked |
Complete acquisition details for Phillips Medisize
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Phillips Medisize
Detailed financials for Phillips Medisize
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Phillips Medisize Comparisons
Peer comparison for Phillips Medisize
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Phillips Medisize
Phillips Medisize operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nephron Pharmaceuticals, Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm and Suanfarma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Sterile pharmaceutical products are manufactured and contract services are provided.
|
|
| Locked | Locked | Locked |
Company specializing in development of Biosimilars
|
|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
|
| Locked | Locked | Locked |
Generics, nutraceuticals, and APIs are developed by Suanfarma.
|
|
| Locked | Locked | Locked |
Biotech company focused on developing innovative therapies for respiratory diseases and immune conditions
|
Detailed competitors of Phillips Medisize
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Phillips Medisize
Complete news archive for Phillips Medisize
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phillips Medisize
Phillips Medisize was founded in 1997 and raised its 1st funding round 4 years after it was founded.
Phillips Medisize is headquartered in Chippenham, United Kingdom.
Will Downie is the current CEO of Phillips Medisize.
Phillips Medisize is a funded company, having raised a total of $15.21M across 2 funding rounds to date.
Phillips Medisize, incorporating Vecturas expertise since 2025, is focused on inhaled drug development. Services are offered in formulation science, device technology, and development for inhalation therapies. Solutions are provided for small molecules, biologics, and complex combinations across pMDI, DPI, nasal inhalers, and nebulizers. Contributions have been made to 13 launched inhaled medicines, benefiting millions globally. Sectors served include pharmaceutical and medtech industries with a focus on respiratory health solutions.
Phillips Medisize's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.
Phillips Medisize offers Dry Powder Inhalers (DPI), Metered Dose Inhalers (pMDI), FOX Vibrating Mesh Nebulizer, and Aria Smart Autoinjector.
Phillips Medisize has made 3 acquisitions, including Activaero, Skyepharma, and Syqe.
Phillips Medisize has 5 investors. Key investors include Boehringer Ingelheim, Molex, Philip Morris International, NVM Private Equity, and Phillips Medisize.